Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00901342 · ClinicalTrials.gov registry record · Phase 2
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Dendreon.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 18
- Study locations
NCT00901342 is a Phase 2 study of Prostate Cancer that has completed, run by Dendreon. The registered enrollment target is 104 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (83% lower). The trial reports 18 study locations across 14 states.
The verdict
NCT00901342, a Phase 2 study of Prostate Cancer, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
Conditions Studied
Interventions
- BIOLOGICAL sipuleucel-T
Study Locations (18)
New York
- NYU Cancer Institute - New York
- Mount Sinai School of Medicine Department of Urology - New York
- Columbia University Medical Center - New York
Illinois
- The University of Chicago Medical Center - Chicago
- Oncology Specialists, S.C. - Park Ridge
Maryland
- Hematology Oncology Consultants - Greenbelt
- Myron I. Murdock MD LLC - Greenbelt
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Indiana
- Indiana University Department of Urology - Indianapolis
Maine
- Maine Center for Cancer Medicine - Scarborough
New Jersey
- John Theurer Cancer Center at Hackensack - Hackensack
North Carolina
- GU Oncology Research Program - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00901342
The ClinicalTrials.gov registry entry for NCT00901342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which sipuleucel-T is the first listed.
NCT00901342 reports 18 study locations spanning 14 distinct geographic areas - top geographies include New York, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT00901342 about?
NCT00901342 is a clinical study titled "Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer". This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
What is the current status of trial NCT00901342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2009-10. Estimated completion is 2015-06.
What conditions does trial NCT00901342 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00901342?
The interventions under investigation include: sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00901342?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00901342 being conducted?
This trial has 18 study locations across District of Columbia, Illinois, Indiana, Maine, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.